Payment overview · 2025
General Payments
$10,318.67
27 reported records · 8 companies
Healthcare provider profile · identity verified
Broderick Eaton, DO
Allopathic & Osteopathic Physicians|Family Medicine · WYNNE, AR · NPI 1992115646
Verified facts
What the public records show
CMS Open Payments records show Broderick Eaton, DO received $10,318.67 in general payments during 2025 across 27 reported records.
Amgen Inc. accounted for 98.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synjardy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $10,118.86 | 98.1% | 18 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.92 | 0.7% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $33.10 | 0.3% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $28.45 | 0.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.23 | 0.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $15.73 | 0.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.63 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.75 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,450.00 | 7 |
| Travel and Lodging | $475.97 | 4 |
| Food and Beverage | $392.70 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $10,003.48 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.42 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $74.92 | 3 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $51.37 | 2 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $33.10 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
69 | 22 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 96 |
| Gabapentin | Gabapentin | 195 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 59 |
| Omeprazole | Omeprazole | 162 | 45 |
| Furosemide | Furosemide | 134 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 30 |
| Lisinopril | Lisinopril | 125 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 35 |
| Potassium Chloride | Potassium Chloride | 107 | 33 |
| Metformin Hcl | Metformin Hcl | 106 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 104 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 32 |
| Jardiance | Empagliflozin | 95 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 35 |
| Losartan Potassium | Losartan Potassium | 87 | 27 |
| Carvedilol | Carvedilol | 86 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 11 |
| Trazodone Hcl | Trazodone Hcl | 73 | 17 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 72 | 16 |
| Eliquis | Apixaban | 69 | 22 |
| Ozempic | Semaglutide | 67 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | suppressed |
| Meloxicam | Meloxicam | 64 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 20 |
| Farxiga | Dapagliflozin Propanediol | 58 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 22 |
| Lorazepam | Lorazepam | 56 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 51 | 11 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Mounjaro | Tirzepatide | 47 | 12 |
| Tramadol Hcl | Tramadol Hcl | 46 | 19 |
| Simvastatin | Simvastatin | 44 | 13 |
| Chlorthalidone | Chlorthalidone | 43 | 17 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Pregabalin | Pregabalin | 41 | 19 |
| Famotidine | Famotidine | 40 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 40 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Rybelsus | Semaglutide | 36 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Nystatin | Nystatin | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | 14 |
| Torsemide | Torsemide | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 13 |
| Prednisone | Prednisone | 24 | 21 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Azithromycin | Azithromycin | 23 | 23 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Baclofen | Baclofen | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | 11 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Glipizide | Glipizide | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Allopurinol | Allopurinol | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Celecoxib | Celecoxib | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $10,318.67 · 27 records | Amgen Inc. | ABRYSVO, BRIXADI, CAPLYTA, CAPVAXIVE, COMIRNATY, GARDASIL 9, JARDIANCE, OTEZLA, PENBRAYA, PREVNAR 20, QUTENZA, REPATHA, TRUMENBA, TZIELD | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error